Cited by 197Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement DisordersNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: A double-blind, placebo-controlled study

Maricle, Robert A., Nutt, John G., Valentine, Rita J., Carter, Julie H.·1995·Neurology

DOI 10.1212/wnl.45.9.1757

Open this paper in CoChat — free account

Abstract

We investigated the effect of levodopa on mood and anxiety in eight Parkinson's disease patients with motor fluctuations. Each patient received 0.0-, 0.5-, and 1.0-mg/kg/hr levodopa infusions in randomly assigned order under double-blind conditions on consecutive days. Mood elevation and anxiety reduction based on half-hourly patient rating and a corresponding increase in tapping speed occurred with active drug infusion but not placebo infusion. The effects were dose related. The higher-dose infusion rate produced more rapid onset, greater magnitude, and longer duration of response. We conclude that mood and anxiety fluctuations related to levodopa dosing are robust pharmacologic, and not placebo, effects.

Integrity signals

Registry

Crossref · 10.1212/wnl.45.9.1757

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

American Journal of Psychiatry celebrates 150th anniversary
Andreasen, N. C. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.1 · Cited by 204
The social construction of mental illness
Eisenberg, L. (1988) · Psychological Medicine · doi:10.1017/s0033291700001823 · Cited by 145
The on-off phenomenon.
Lees, A. J. (1989) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.52.suppl.29 · Cited by 125
Verbal learning differences in epileptic patients with left and right temporal lobe foci - a pharmacologically induced phenomenon?
Durwen, H. F., & Elger, C. E. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1993.tb04066.x · Cited by 48
Preface
(1993) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1993.tb00001.x · Cited by 10

Show all 5 references

Research works printed but not linked: 7

Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992;149:443-454.
Hantz P, Caradoc-Davies G, Caradoc-Davies T, Weatherall M, Dixon G. Depression in Parkinson's disease. Am J Psychiatry 1994;151:1010-1014.
Henderson R, Kurlan R, Kersum JM, Como P. Preliminary examination of the comorbidity of anxiety and depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992;4:257-264.
Menza MA, Sage J, Marshall E, Cody R, Duvoisin R. Mood changes and ``On-off'' phenomena in Parkinson's disease. Mov Disord 1990;5:148-151.
Nissenbaum H, Quinn NP, Brown RG, Toone B, Gotham AM, Marsden CD. Mood swings associated with the ``on-off'' phenomenon in Parkinson's disease. Psychol Med 1987;17:899-904.
Maricle RA, Nutt JG, Carter JH. Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion. Mov Disord 1995;10:329-332.
Nutt JG, Woodward WR, Carter JH, Gancher ST. Effects of long-term therapy on the pharmacodynamics of levodopa: relation to on-off phenomenon. Arch Neurol 1992;49:1123-1130.

Sorted by citations

The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system
Rémy, P., Doder, M., Lees, A. J., Turjanski, N., & Brooks, D. J. (2005) · Brain · doi:10.1093/brain/awh445 · Cited by 1,090
Nonmotor fluctuations in Parkinson’s disease: Frequent and disabling
Witjas, T., Kaphan, E., Azulay, J. P., Blin, O., Ceccaldi, M., Pouget, J., Poncet, M., & Chérif, A. A. (2002) · Neurology · doi:10.1212/wnl.59.3.408 · Cited by 642
Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease
Funkiewiez, A. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2002.009803 · Cited by 568
Neuropsychiatric symptoms in Parkinson's disease
Aarsland, D., Marsh, L., & Schrag, A. (2009) · Movement Disorders · doi:10.1002/mds.22589 · Cited by 320
Behavioural disorders, Parkinson's disease and subthalamic stimulation
Houéto, J. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.6.701 · Cited by 489
Deep brain stimulation: Neuropsychological and neuropsychiatric issues
Voon, V., Kubu, C. S., Krack, P., Houéto, J., & Tröster, A. I. (2006) · Movement Disorders · doi:10.1002/mds.20963 · Cited by 402
Nonmotor fluctuations in Parkinson disease
Storch, A., Schneider, C. B., Wolz, M., Stürwald, Y., Nebe, A., Odin, P., Mahler, A., Fuchs, G., Jost, W. H., Chaudhuri, К. R., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e318285c0ed · Cited by 380
Motivation, reward, and Parkinson's disease: influence of dopatherapy
Czernecki, V. (2002) · Neuropsychologia · doi:10.1016/s0028-3932(02)00108-2 · Cited by 336
Deep brain stimulation: Preoperative issues
Lang, A. E., Houéto, J., Krack, P., Kubu, C. S., Lyons, K. E., Moro, E., Ondo, W. G., Pahwa, R., Poewe, W. H., Tröster, A. I., et al. (2006) · Movement Disorders · doi:10.1002/mds.20955 · Cited by 308
Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease
Funkiewiez, A., Ardouin, C., Krack, P., Fraix, V., Blercom, N. V., Xie, J., Moro, E., Benabid, A., & Pollak, P. (2003) · Movement Disorders · doi:10.1002/mds.10441 · Cited by 266
Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study
Rektorová, I., Rektor, I., Bareš, M., Dostál, V., Ehler, E., Fanfrdlová, Z., Fiedler, J., Klajblová, H., Kulišťák, P., Ressner, P., et al. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00612.x · Cited by 248
Depression in Parkinson's disease - a review
LIEBERMAN, A. N. (2005) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00536.x · Cited by 244
Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease
Volkmann, J., Daniels, C., & Witt, K. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.111 · Cited by 232
Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease
Burn, D. J. (2002) · Movement Disorders · doi:10.1002/mds.10114 · Cited by 223
Psychiatric aspects of Parkinson?s disease: An Update
Schrag, A. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0483-3 · Cited by 200
Behavioral phenotyping of mouse models of Parkinson's disease
Taylor, T. N., Greene, J. G., & Miller, G. W. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.03.004 · Cited by 212
Parkinson’s disease and anxiety
Walsh, K., & Bennett, G. A. (2001) · Postgraduate Medical Journal · doi:10.1136/pmj.77.904.89 · Cited by 193
Anxiety in Parkinson’s disease: A critical review of experimental and clinical studies
Prediger, R. D. S., Matheus, F. C., Schwarzbold, M. L., Lima, M. M. S., & Vital, M. A. B. F. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.039 · Cited by 190
Behavioral characterization of the 6-hydroxidopamine model of Parkinson’s disease and pharmacological rescuing of non-motor deficits
Carvalho, M. M., Campos, F. L., Coimbra, B., Pêgo, J. M., Rodrigues, C., Lima, R., Rodrigues, A. J., Sousa, N., & Salgado, A. J. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-14 · Cited by 184
The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations
Martínez‐Fernández, R., Schmitt, E., Martínez‐Martín, P., & Krack, P. (2016) · Movement Disorders · doi:10.1002/mds.26731 · Cited by 170
Pharmacokinetic Optimisation in the Treatment of Parkinson???s Disease
Nyholm, D. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645020-00001 · Cited by 163
Depressive symptoms in Parkinson's disease are related to reduced [123I]FP-CIT binding in the caudate nucleus
Vriend, C., Raijmakers, P. G. H. M., Veltman, D. J., van Dijk, K. D., van der Werf, Y. D., Foncke, E. M. J., Smit, J. H., Berendse, H. W., & van den Heuvel, O. A. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304811 · Cited by 153
Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease
Merims, D., & Giladi, N. (2007) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.09.007 · Cited by 148
Factors affecting the quality of life of patients with idiopathic Parkinson's disease-a cross-sectional study in an outpatient clinic attendees
Sławek, J. W., Derejko, M., & Lass, P. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.04.006 · Cited by 145
Évaluation des troubles comportementaux hyper- et hypodopaminergiques dans la maladie de Parkinson
Ardouin, C., Chéreau, I., Llorca, P., Lhommée, E., Durif, F., Pollak, P., & Krack, P. (2009) · Revue Neurologique · doi:10.1016/j.neurol.2009.06.003 · Cited by 134
Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease
Albanese, A., Bonuccelli, U., Brefel‐Courbon, C., Chaudhuri, К. R., Colosimo, C., Eichhorn, T. E., Melamed, E., Pollak, P., van Laar, T., & Zappia, M. (2001) · Movement Disorders · doi:10.1002/mds.1069 · Cited by 131
Potential mechanisms underlying anxiety and depression in Parkinson's disease: Consequences of l-DOPA treatment
Jaunarajs, K. L. E., Angoa‐Pérez, M., Kuhn, D. M., & Bishop, C. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.06.007 · Cited by 129
Subthalamic Stimulation in Parkinson Disease
Houéto, J., Mallet, L., Mesnage, V., du Montcel, S. T., Béhar, C., Gargiulo, M., Torny, F., Pélissolo, A., Welter, M., & Agid, Y. (2006) · Archives of Neurology · doi:10.1001/archneur.63.8.1090 · Cited by 120
The dopamine transporter: Importance in Parkinson's disease
Nutt, J. G., Carter, J. H., & Sexton, G. J. (2004) · Annals of Neurology · doi:10.1002/ana.20089 · Cited by 118
Self-citation
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double‐blind, placebo‐controlled, multicenter study
Hanagasi, H. A., Gurvit, H. I., Unsalan, P., Horozoğlu, H., Tuncer, N., Feyzioğlu, A., Günal, D. İ., Yener, G., Çakmur, R., Sahin, H. A., et al. (2011) · Movement Disorders · doi:10.1002/mds.23738 · Cited by 113
Absence of dopamine D4 receptors results in enhanced reactivity to unconditioned, but not conditioned, fear
Falzone, T. L., Gelman, D. M., Young, J. I., Grandy, D. K., Low, M. J., & Rubinstein, M. (2002) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01842.x · Cited by 109
Personality Traits and Striatal Dopamine Synthesis Capacity in Healthy Subjects
Laakso, A., Wallius, E., Kajander, J., Bergman, J. R., Eskola, O., Solin, O. H., Ilonen, T., Salokangas, R. K. R., Syvälahti, E. K. G., & Hietala, J. A. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.5.904 · Cited by 108
Depression and impulse control disorders in Parkinson׳s disease: two sides of the same coin?
Vriend, C., Pattij, T., van der Werf, Y. D., Voorn, P., Booij, J., Rutten, S., Berendse, H. W., & van den Heuvel, O. A. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.11.001 · Cited by 106
Combined Rasagiline and Antidepressant Use in Parkinson Disease in the ADAGIO Study
Smith, K. M., Eyal, E., & Weintraub, D. A. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2472 · Cited by 106
Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients
Erro, R., Pappatà, S., Amboni, M., Vicidomini, C., Longo, K., Santangelo, G., Picillo, M., Vitale, C., Moccia, M., Giordano, F., et al. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.05.022 · Cited by 104
Emotional manifestations of PD: Neurobiological basis
Castrioto, A., Thobois, S., Carnicella, S., Maillet, A., & Krack, P. (2016) · Movement Disorders · doi:10.1002/mds.26587 · Cited by 105
Neuropsychiatric Complications of Medical and Surgical Therapies for Parkinson’s Disease
Burn, D. J., & Tröster, A. I. (2004) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988704267466 · Cited by 95
Depression in Parkinson's disease
Burn, D. J. (2002) · European Journal of Neurology · doi:10.1046/j.1468-1331.9.s3.6.x · Cited by 99
Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease
Funkiewiez, A., Ardouin, C., Cools, R., Krack, P., Fraix, V., Batir, A., Chabardès, S., Benabid, A., Robbins, T., & Pollak, P. (2006) · Movement Disorders · doi:10.1002/mds.21029 · Cited by 103
Affective symptoms in multiple system atrophy and Parkinson's disease: response to levodopa therapy
Fetoni, V., Soliveri, P., Monza, D., Testa, D., & Girotti, F. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.4.541 · Cited by 88
What a neurologist should know about depression in Parkinson’s disease
Timmer, M. H. M., Beek, M. H. C. T. V., Bloem, B. R., & Esselink, R. A. J. (2017) · Practical Neurology · doi:10.1136/practneurol-2017-001650 · Cited by 87
Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat
Jaunarajs, K. L. E., Dupre, K. B., Ostock, C. Y., Button, T., Terrence Deak, B., & Bishop, C. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833e7e80 · Cited by 87
Deep brain stimulation of the subthalamic nucleus in Parkinson's Disease 1993 – 2003: where are we 10 years on?
Ashkan, K., Wallace, B. A., Bell, B., & Benabid, A. (2004) · British Journal of Neurosurgery · doi:10.1080/02688690410001660427 · Cited by 84
Emotional dysfunction in Parkinson's disease.
Blonder, L. X., & Slevin, J. T. (2011) · PubMed Central · doi:10.3233/ben-2011-0329 · Cited by 86
Interactions between deep brain stimulation and levodopa in Parkinson’s disease
Nutt, J. G., Rufener, S. L., Carter, J. H., Anderson, V. C., Pahwa, R., Hammerstad, J. P., & Burchiel, K. J. (2001) · Neurology · doi:10.1212/wnl.57.10.1835 · Cited by 82
Self-citation
Relationship Between Mood and Motor Fluctuations in Parkinson's Disease
Richard, I. H., Justus, A. W., & Kurlan, R. (2001) · Journal of Neuropsychiatry · doi:10.1176/jnp.13.1.35 · Cited by 81
Dopaminergic Mechanisms Underlying Normal Variation in Trait Anxiety
Berry, A. S., White, R. L., Furman, D. J., Naskolnakorn, J. R., Shah, V. D., D’Esposito, M., & Jagust, W. J. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.2382-18.2019 · Cited by 83
Effects of Ropinirole on Nonmotor Symptoms of Parkinson Disease
Rektorová, I., Baláž, M., Svátová, J., Zárubová, K., Honig, I., Dostal, V., Sedláčková, S., Nestrašil, I., Mastík, J., Bareš, M., et al. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31815d25ce · Cited by 77
Acute effects of immediate and controlled‐release levodopa on mood in Parkinson's disease: A double‐blind study
Kulisevsky, J., Pascual-Sedano, B., Barbanoj, M., Gironell, A., Pagonabarraga, J., & García-Sánchez, C. (2007) · Movement Disorders · doi:10.1002/mds.21205 · Cited by 77
Levodopa Challenge Neuroimaging of Levodopa-Related Mood Fluctuations in Parkinson's Disease
BLACK, K. J., Hershey, T. G., Hartlein, J. M., Carl, J. L., & Perlmutter, J. S. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300632 · Cited by 75
The longitudinal impact of depression on disability in Parkinson disease
Pontone, G. M., Bakker, C. C., Chen, S., Mari, Z. K., Marsh, L., Rabins, P. V., Williams, J. R., & Bassett, S. S. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4350 · Cited by 72
Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease
Delpont, B., Lhommée, E., Klinger, H., Schmitt, E., Bichon, A., Fraix, V., Castrioto, A., Quésada, J.-L., Pélissier, P., Kistner, A., et al. (2017) · Movement Disorders · doi:10.1002/mds.27101 · Cited by 72
Dopaminergic Therapies for Non-motor Symptoms in Parkinson’s Disease
Schaeffer, E., & Berg, D. (2017) · CNS Drugs · doi:10.1007/s40263-017-0450-z · Cited by 69
Differential Effects of L-Dopa and Subthalamic Stimulation on Depressive Symptoms and Hedonic Tone in Parkinson's Disease
Witt, K., Daniels, C., Herzog, J., Lorenz, D., Volkmann, J., Reiff, J., Mehdorn, H. M., Deuschl, G., & Krack, P. (2006) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.18.3.397 · Cited by 68
Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test
Fabbri, M., Coelho, M. M., Guedes, L. C., Chendo, I., Sousa, A. C., Rosa, M. M., Abreu, D., Costa, N., Godinho, C., Antonini, A., et al. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.02.007 · Cited by 67
Neuropsychiatric aspects of parkinson’s disease
Aarsland, D., & Karlsen, K. (1999) · Current Psychiatry Reports · doi:10.1007/s11920-999-0011-3 · Cited by 65
Effect of Attentional Focus Instructions on Motor Learning and Performance of Patients with Central Nervous System and Musculoskeletal Disorders: a Systematic Review
Piccoli, A., Rossettini, G., Cecchetto, S., Viceconti, A., Ristori, D., Turolla, A., Maselli, F., & Testa, M. (2018) · Journal of Functional Morphology and Kinesiology · doi:10.3390/jfmk3030040 · Cited by 67
Depression in Parkinson's disease: its prevalence, diagnosis, and neurochemical background
Yamamoto, M. (2001) · Journal of Neurology · doi:10.1007/pl00022917 · Cited by 64
Recognition and management of neuropsychiatric complications in Parkinson's disease
Ferreri, F., Agbokou, C., & Gauthier, S. G. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.060542 · Cited by 63
Clinical Features and Comorbidity of Mood Fluctuations in Parkinson's Disease
Racette, B. A., Hartlein, J. M., Hershey, T. G., Mink, J. W., Perlmutter, J. S., & BLACK, K. J. (2002) · Journal of Neuropsychiatry · doi:10.1176/jnp.14.4.438 · Cited by 63
Treatment options for depression and psychosis in Parkinson's disease
Poewe, W. H., & Seppi, K. (2001) · Journal of Neurology · doi:10.1007/pl00007821 · Cited by 59
Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion
Isacson, D. G. L., Bingefors, K., Kristiansen, I. S., & Nyholm, D. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01049.x · Cited by 58
Deep brain stimulation of the subthalamic nucleus in Parkinson’s disease: From history to the interaction with the monoaminergic systems
Faggiani, E., & Benazzouz, A. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.07.003 · Cited by 57
Depression in Parkinsonʼs disease
Brooks, D. J., & Doder, M. (2001) · Current Opinion in Neurology · doi:10.1097/00019052-200108000-00006 · Cited by 58
Changing Gears – DBS For Dopaminergic Desensitization in Parkinson's Disease?
Weiß, D., Volkmann, J., Fasano, A. A., Kühn, A. A., Krack, P., & Deuschl, G. (2021) · Annals of Neurology · doi:10.1002/ana.26164 · Cited by 53
Body awareness training in the treatment of wearing-off related anxiety in patients with Parkinson's disease: Results from a pilot randomized controlled trial.
Ghielen, I., van Wegen, E. E. H., Rutten, S., de Goede, C. J. T., Houniet-de Gier, M., Collette, E. H., Burgers-Bots, I. A. L., Twisk, J. W. R., Kwakkel, G., Vermunt, K., et al. (2017) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2017.09.008 · Cited by 50
Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti‐reward
Evans, A. H., Lawrence, A. D., Cresswell, S. A., Katzenschlager, R., & Lees, A. J. (2010) · Movement Disorders · doi:10.1002/mds.22898 · Cited by 51
Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study☆☆Supplementary
Bearn, J., Evans, A. H., Kelleher, M., Turner, K., & Lees, A. J. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.06.005 · Cited by 52
Non-Motor Aspects of Parkinson's Disease
Borek, L. L., Amick, M. M., & Friedman, J. H. (2006) · CNS Spectrums · doi:10.1017/s1092852900013560 · Cited by 53
Serotonin transporter binding and anxiety symptoms in Parkinson’s disease
Joling, M., van den Heuvel, O. A., Berendse, H. W., Booij, J., & Vriend, C. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316193 · Cited by 50
Duodenal levodopa infusion for the treatment of Parkinson’s disease
Samanta, J., & Hauser, R. A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.5.657 · Cited by 48
Balance problems with Parkinson's disease: are they anxiety-dependent?
Pasman, E. P., Murnaghan, C. D., Bloem, B. R., & Carpenter, M. G. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2010.12.050 · Cited by 47
Correlation between Tapping and Inserting of Pegs in Parkinson's Disease
Müller, T. H., Schafer, S. L., Kuhn, W., & Przuntek, H. (2000) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100001062 · Cited by 47
Psychostimulant effect of levodopa: reversing sensitisation is possible
Castrioto, A., Kistner, A., Klinger, H., Lhommée, E., Schmitt, E., Fraix, V., Chabardès, S., Mertens, P., Quesada, J., Broussolle, E., et al. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302444 · Cited by 42
Anxiety disorders in Parkinson's disease
Marsh, L. (2000) · International Review of Psychiatry · doi:10.1080/09540260020002532 · Cited by 45
Effects of gypenosides on anxiety disorders in MPTP-lesioned mouse model of Parkinson׳s disease
Shin, K. S., Zhao, T., Choi, H. S., Hwang, B. Y., Lee, C. K., & Lee, M. K. (2014) · Brain Research · doi:10.1016/j.brainres.2014.04.015 · Cited by 44
The combined depletion of monoamines alters the effectiveness of subthalamic deep brain stimulation
Faggiani, E., Delaville, C., & Benazzouz, A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.07.010 · Cited by 43
Nonmotor Fluctuations in Parkinson's Disease.
Franke, C., & Storch, A. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.05.021 · Cited by 54
A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability
Schneider, R. B., Auinger, P., Tarolli, C. G., Iourinets, J., Gil-Díaz, M. C., & Richard, I. H. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.10.020 · Cited by 39
Depletion of AADC activity in caudate nucleus and putamen of Parkinson’s disease patients; implications for ongoing AAV2-AADC gene therapy trial
Ciesielska, A., Samaranch, L., Sebastián, W. S., Dickson, D. W., Goldman, S. M., Forsayeth, J., & Bankiewicz, K. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169965 · Cited by 39
The effects of anxiety and external attentional focus on postural control in patients with Parkinson's disease
Jazaeri, S. Z., Azad, A., Mehdizadeh, H., Habibi, S. A., Najafabadi, M. M., Saberi, Z. S., Rahimzadegan, H., Moradi, S., Behzadipour, S., Parnianpour, M., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192168 · Cited by 38
Medical treatment of Parkinson’s disease
Fahn, S. (1998) · Journal of Neurology · doi:10.1007/pl00007742 · Cited by 38
Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease
Hirao, K., Pontone, G. M., & Smith, G. S. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.11.010 · Cited by 38
Virtually-induced threat in Parkinson's: Dopaminergic interactions between anxiety and sensory–perceptual processing while walking
Martens, K. A. E., Ellard, C. G., & Almeida, Q. J. (2015) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2015.05.015 · Cited by 36
Neuropsychiatric Complications of Parkinson Disease Treatments: Importance of Multidisciplinary Care
Taylor, J., Anderson, W. S., Brandt, J., Mari, Z. K., & Pontone, G. M. (2016) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.08.017 · Cited by 36
Anxiety‐provoked gait changes are selectively dopa‐responsive in Parkinson's disease
Martens, K. A. E., Ellard, C. G., & Almeida, Q. J. (2015) · European Journal of Neuroscience · doi:10.1111/ejn.12928 · Cited by 36
Pharmacologic Treatment of Anxiety Disorders in Parkinson Disease
Pontone, G. M., Williams, J. R., Anderson, K. E., Chase, G. A., Goldstein, S. R., Grill, S. E., Hirsch, E. S., Lehmann, S. W., Little, J. T., Margolis, R. L., et al. (2013) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2012.10.023 · Cited by 36
Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues
Claßen, J., Koschel, J., Oehlwein, C., Seppi, K., Urban, P. P., Winkler, C., Wüllner, U., & Storch, A. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1757-0 · Cited by 34
Effect of Levodopa on Reward and Impulsivity in a Rat Model of Parkinson’s Disease
Carvalho, M. M., Campos, F. L., Marques, M., Soares‐Cunha, C., Kokras, N., Dalla, C., Leite‐Almeida, H., Sousa, N., & Salgado, A. J. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00145 · Cited by 39
Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies
Lai, T. T., Gericke, B., Feja, M., Conoscenti, M. A., Zelikowsky, M., & Richter, F. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00547-4 · Cited by 34
Management of behavioral and psychiatric problems in Parkinson's disease
Rabinstein, A. A., & Shulman, L. M. (2000) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(00)00039-0 · Cited by 30
Maladie de Parkinson : de la physiopathologie des troubles psychiques à la maîtrise du traitement dopaminergique
Thobois, S., Ardouin, C., Schmitt, E., Lhommée, E., Klinger, H., Xie, J., Lagrange, C., Kistner, A., Kombo, M. A., Fleury, V., et al. (2010) · Revue Neurologique · doi:10.1016/j.neurol.2010.07.006 · Cited by 28
Spontaneous locomotor activity and L-DOPA-induced dyskinesia are not linked in 6-OHDA parkinsonian rats
Sgroi, S., Kaelin‐Lang, A., & Capper-Loup, C. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00331 · Cited by 28
Behavioral disturbances in Parkinson's disease
Anderson, K. E. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.3/kanderson · Cited by 28
Clinical risk–benefit assessment of dopamine agonists
Möller, J. C., Eggert, K. M., Unger, M. M., Odin, P., Chaudhuri, К. R., & Oertel, W. H. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02214.x · Cited by 27
Dopamine D1Agonist Activates Temporal Lobe Structures in Primates
BLACK, K. J., Hershey, T. G., Gado, M. H., & Perlmutter, J. S. (2000) · Journal of Neurophysiology · doi:10.1152/jn.2000.84.1.549 · Cited by 24
Phenomenology of Atypical Anxiety Disorders in Parkinson's Disease: A Systematic Review
Dissanayaka, N. N., Forbes, E. J., Perepezko, K. M., Leentjens, A. F. G., Dobkin, R. D., Dujardin, K., & Pontone, G. M. (2022) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2022.02.004 · Cited by 23
The Human Experience with Intravenous Levodopa
Siddiqi, S., Abraham, N., Geiger, C. L., Karimi, M., Perlmutter, J. S., & BLACK, K. J. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00307 · Cited by 22
Depression in alpha-synucleinopathies: prevalence, pathophysiology and treatment
Stefanova, N., Seppi, K., Scherfler, C., Puschban, Z., & Wenning, G. K. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6301-6_23 · Cited by 22

Authors: Maricle, R. A., Nutt, J. G., Valentine, R. J., & Carter, J. H.
Affiliations: Oregon Health & Science University (US)
ORCID: Nutt, John G.
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1995-09
Volume: 45
Issue: 9
Pages: 1757-1760
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/wnl.45.9.1757
OpenAlex: W2107507666
Cited by: 197
References: 5
Citations by year: 2026: 2 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 3 · 2018: 5 · 2017: 16 · 2016: 10 · 2015: 11 · 2014: 7 · 2013: 11 · 2012: 6
FWCI: 0.61
Type: journal article
Language: en
Open access: closed
Locations: Neurology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Neurological Disorders and Stroke (R01NS021062)
National Center for Research Resources (RR-00334, M01RR000334)
NIH Clinical Center
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: levodopa, Parkinson's disease, motor fluctuations, mood improvement, anxiety, levodopa infusion, placebo effect, tapping speed
MeSH terms: Affect, Aged, Anxiety, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Levodopa, Male, Middle Aged, Parkinson Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: A double-blind, placebo-controlled study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks